4-Methylbenzylidene Camphor Ethylhexyl Methoxycinn
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- 4-Methylbenzylidene Camphor Ethylhexyl Methoxycinn
- Multi-ingredient Sunscreen Formula: Insufficient Evidence for Drug Repurposing Assessment
Multi-ingredient Sunscreen Formula: Insufficient Evidence for Drug Repurposing Assessment
One-Sentence Summary
This candidate is a complex eight-ingredient formulation composed primarily of topical UV filters (4-methylbenzylidene camphor, ethylhexyl methoxycinnamate, octocrylene, phenylbenzimidazole sulfonic acid, methylene bis-benzotriazolyl tetramethylbutylphenol) and cosmetic actives (honey, hydrolysed marine collagen, saccharomyces lysate), with no registered marketing authorization in Taiwan or the US. The TxGNN pipeline did not generate any predicted new indications for this multi-ingredient entry, as the submission could not be resolved to a single DrugBank-mapped compound. Current data is insufficient to support a repurposing evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — no marketing authorization on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (knowledge-graph prediction stage not reached) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No repurposing prediction was generated by TxGNN for this entry, so a mechanistic rationale cannot be formulated in the conventional sense.
The submitted drug string is a multi-ingredient mixture rather than a single molecular entity. TxGNN operates on individual DrugBank-mapped compounds; without a valid DrugBank ID, the knowledge-graph traversal cannot be initiated. The five UV-filter components are primarily topically applied photoprotective agents approved for cosmetic/sunscreen use, while honey, hydrolysed marine collagen, and saccharomyces lysate are functional skin-conditioning excipients. None of these components carry systemic pharmacological profiles in DrugBank that would anchor a knowledge-graph edge traversal toward a new therapeutic indication.
Before a meaningful repurposing analysis can proceed, this submission must be decomposed into individual INN-level entries, each independently mapped to a DrugBank ID and re-submitted to the pipeline.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline returned zero predicted indications because the entry could not be resolved to a single DrugBank-mapped compound, and no marketing authorization, safety profile, or clinical evidence is available for this multi-ingredient cosmetic formulation as a unified entity.
To proceed, the following is needed:
- Decompose the ingredient string into individual INN-level compounds and submit each separately to the TxGNN pipeline (priority candidates: octocrylene, ensulizole/phenylbenzimidazole sulfonic acid, ethylhexyl methoxycinnamate)
- Obtain DrugBank IDs for each individual active ingredient to enable knowledge-graph edge traversal
- Retrieve MOA data for each individual compound from DrugBank to support mechanistic plausibility analysis
- Clarify the repurposing intent — if the goal is to investigate a specific UV filter for a systemic therapeutic indication, narrow the query to that single compound before resubmission
- Retrieve safety data from TFDA product monograph (if any) or the relevant cosmetic/pharmaceutical regulatory dossier for individual components
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.